SNHG20 and gastric cancer: The expressions of E-cadherin and p21 can be markedly suppressed when SNHG20 is overexpressed in MKN45 and BGC-823 cells via binding to the enhancer of zeste homolog 2 (EZH2) and mediating the GSK-3β/β-catenin signalling pathway, and SNHG20 can be a therapeutic target for GC (Liu et al., 2017).